Nardulli Patrizia, Ballini Andrea, Zamparella Maria, De Vito Danila
S.C. Farmacia e UMACA IRCCS Istituto Tumori "Giovanni Paolo II", Viale O. Flacco 65, 70124 Bari, Italy.
Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy.
Microorganisms. 2023 Nov 17;11(11):2797. doi: 10.3390/microorganisms11112797.
The increasing misuse of antibiotics in human and veterinary medicine and in agroecosystems and the consequent selective pressure of resistant strains lead to multidrug resistance (AMR), an expanding global phenomenon. Indeed, this phenomenon represents a major public health target with significant clinical implications related to increased morbidity and mortality and prolonged hospital stays. The current presence of microorganisms multi-resistant to antibiotics isolated in patients is a problem because of the additional burden of disease it places on the most fragile patients and the difficulty of finding effective therapies. In recent decades, international organizations like the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) have played significant roles in addressing the issue of AMR. The ECDC estimates that in the European Union alone, antibiotic resistance causes 33,000 deaths and approximately 880,000 cases of disability each year. The epidemiological impact of AMR inevitably also has direct economic consequences related not only to the loss of life but also to a reduction in the number of days worked, increased use of healthcare resources for diagnostic procedures and the use of second-line antibiotics when available. In 2015, the WHO, recognising AMR as a complex problem that can only be addressed by coordinated multi-sectoral interventions, promoted the One Health approach that considers human, animal, and environmental health in an integrated manner. In this review, the authors try to address why a collaboration of all stakeholders involved in AMR growth and management is necessary in order to achieve optimal health for people, animals, plants, and the environment, highlighting that AMR is a growing threat to human and animal health, food safety and security, economic prosperity, and ecosystems worldwide.
抗生素在人类医学、兽医学以及农业生态系统中的滥用现象日益严重,由此产生的耐药菌株的选择性压力导致了多重耐药性(AMR)这一全球范围不断扩大的现象。事实上,这一现象已成为一个主要的公共卫生目标,具有与发病率和死亡率上升以及住院时间延长相关的重大临床意义。患者体内分离出的对多种抗生素耐药的微生物的存在是一个问题,因为这给最脆弱的患者带来了额外的疾病负担,并且难以找到有效的治疗方法。近几十年来,世界卫生组织(WHO)和欧洲疾病预防控制中心(ECDC)等国际组织在解决AMR问题方面发挥了重要作用。ECDC估计,仅在欧盟,抗生素耐药性每年就导致3.3万人死亡和约88万例残疾。AMR的流行病学影响不可避免地也会产生直接的经济后果,这不仅与生命损失有关,还与工作日减少、诊断程序中医疗资源使用增加以及在有二线抗生素时的使用有关。2015年,WHO认识到AMR是一个复杂的问题,只能通过多部门协调干预来解决,于是推广了“同一健康”方法,该方法以综合方式考虑人类、动物和环境健康。在这篇综述中,作者试图阐述为什么参与AMR产生和管理的所有利益相关者进行合作对于实现人类、动物、植物和环境的最佳健康是必要的,强调AMR对全球人类和动物健康、食品安全与保障、经济繁荣以及生态系统构成了日益严重的威胁。